Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Searching the literature to explain unexpected clinical observations: all that glitters is not gold.

European journal of internal medicine·2023

Same author

All-cause mortality during the influenza season 2019-2020: comparison with previous influenza seasons in the territory of the local health authority "Central Tuscany", Italy.

Annali di igiene : medicina preventiva e di comunita·2021

Same author

Synergistic interactions among growing stressors increase risk to an Arctic ecosystem.

Nature communications·2020

Same author

Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2019

Same author

Pathogenesis and diagnosis of disseminated intravascular coagulation.

International journal of laboratory hematology·2018

Same author

The role of ADAMTS-13 in the coagulopathy of sepsis.

Journal of thrombosis and haemostasis : JTH·2018

Search research articles

Related Experiment Video

Updated: May 31, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Anticoagulants. Old and new.

M Levi¹, E S Eerenberg, P W Kampuisen

¹Dept. of Medicine, University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands. m.m.levi@amc.uva.nl

Hamostaseologie

|June 21, 2011

Summary

This summary is machine-generated.

Anticoagulants prevent thrombosis but increase bleeding risk. New agents show similar efficacy with better safety, though reversal strategies are still being developed.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Experiment Videos

Last Updated: May 31, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

Pharmacology
Cardiology
Hematology

Background:

Anticoagulants are crucial for managing thrombotic disorders.
Major bleeding occurs in ~0.5% of patients annually, potentially higher in real-world practice.
Bleeding risk is influenced by anticoagulation intensity, management, and patient factors.

Purpose of the Study:

To review the efficacy and safety of anticoagulants.
To discuss bleeding risks and management strategies.
To evaluate newer anticoagulant agents and their reversal.

Main Methods:

Literature review of anticoagulant studies.
Analysis of bleeding incidence and risk factors.
Evaluation of clinical trial data for novel anticoagulants.

Main Results:

Vitamin K antagonists are associated with significant bleeding risks.
Newer anticoagulants demonstrate comparable or superior efficacy with a favorable safety profile.
Reversal of novel anticoagulants is more complex than with vitamin K antagonists.

Conclusions:

Anticoagulants remain vital but carry bleeding risks.
Novel anticoagulants offer potential advantages but require further study regarding reversal.
Optimizing anticoagulant therapy involves balancing efficacy and safety.